Schedule 13G ownership disclosure
Prelude Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 74065P101
Event date: 2025-11-03
- Filing-level shares
- 4,372,124.00
- Percent of class
- 9.9%
- INCYTE CORP
Shares: 4,372,124.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-108459
- Form type
- SCHEDULE 13G
- Filer
- INCYTE CORP
- CIK
- CIK 879169
- Filed
- Nov 07, 2025
- Reporting period
- Nov 03, 2025
- Description
- Schedule 13G beneficial ownership